A phase III study on osilodrostat reported variable effects on tumor size, with patients exhibiting growth (33%), shrinkage (38%), or stability in tumor size over 48 weeks of treatment irrespective of baseline tumor volume or ACTH levels at baseline. This evidence concerns the gene POMC and neoplasm.